Announcement Date: 21 September 2013
Chief Research Analyst for Van Leeuwenhoeck Research
Marcel Wijma MSc
+1 (917) 460 6185 (US)
+31 (6) 4207 3959 (NL) [email protected]
Out licensed program to Calimmune: HIV/AIDS
In March 2012, Benitec announced that it signed an agreement with US based biotech company Calimmune for the use of the ddRNAi technology in the area of HIV/AIDS worldwide. The agreement covers the application of ddRNAi to target up to three key viral and cellular genes identified as significant therapeutic targets to inhibit HIV/AIDS infection. Whilst the terms are commercial in confidence, they are within expected guidelines for biotech companies in the early stage of development.
Competitive Landscape
Peer Group Company Profiles Alnylam Inc. (NASDAQ: ALNM)
